Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

ZYDUSLIFE's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 1.88500
forwardPE 22.20791
debtToEquity 12.20900
earningsGrowth -0.00400
revenueGrowth 0.18000
grossMargins 0.71868
operatingMargins 0.29227
trailingEps 44.94000
forwardEps 0.00000

ZYDUSLIFE's current ratio 1.885, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, ZYDUSLIFE can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
ZYDUSLIFE's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
ZYDUSLIFE's low Debt-to-Equity ratio indicates that the company isn't heavily dependent on debt financing. This lower leverage reduces financial risk and enhances stability, showing that ZYDUSLIFE is well-positioned to manage its obligations without the burden of excessive debt.
Zydus Lifesciences Limited's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

The gradual downward revision of ZYDUSLIFE's price projections signals decreasing confidence in the company's future performance. Analysts are adjusting their expectations, reflecting uncertainty about ZYDUSLIFE's growth potential.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


Analysts have maintained a buy bias for Zydus Lifesciences Limited, which could prompt investors to consider the stock as a viable investment. With this positive outlook, Zydus Lifesciences Limited is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.